Loss of functionality in transplanted pancreatic islets

Pancreatic Islet; The primary cause of the loss of functionality in transplanted pancreatic islets is their low capacity to create new vessels to transport nutrients. Researchers from the University of Barcelona and IDIBAPS have led a study that identifies a protein as the potential modulator in the revascularization of pancreatic islets.

In the study, conducted on diabetic mice with islet transplant from other animals or human islets; so researchers show that grafts without this protein have a higher revascularization, favouring the viability of cells. Regular sugar levels and glucose tolerance were also recovered. The study was coordinate by Ramon Gomis, professor at the Faculty of Medicine and Health Sciences of the University of Barcelona, and Rosa Gasa, researcher in the same group.

The Pancreatic Islet

One of the used strategies in type 1 diabetes treatment base on regenerative medicine; so is pancreatic islet transplantation. Islets are form by different types of cells and produce hormones such as insulin and glucagon. In type 1 diabetes, beta cells in islets responsible for the production of insulin are selectively destroy by an autoimmune process.

For this reason, islet transplantation can restore physiological function in patients with this type of diabetes. Although this transplant is carry out in some centers, it has limitations, such as the chronic administration of immunosuppressants, and it is apply in those cases in which the disease is not properly control. Currently, it is indicate in the context of a kidney transplant, and we opt for a dual vascular kidney-pancreas transplant,” says Ramon Gomis, coordinator of the study.

The regular environment for islets is form by a heavy network of capillaries; so in charge of the arrival of oxygen, hormones and nutrients and the transport of the generate hormones to the blood vessel. During the transplant process, islets are separate from their vascular network and their right function; also survival depends on the ability to create new vessels for the vascular system in the receptor.

Inhibition of the enzyme

Islet implantation is revascularized, but not fast enough. In the article; so they focus on getting enough vessels to keep the islets in optimal condition and improve the success of this strategy for the treatment of type 1 diabetes,” notes researcher Rosa Gasa, coordinator of the study.

In the study, the researchers identify a molecular target PTP1B phosphatase; which would make the transplant pancreatic islets viable. The results show the inhibition of this enzyme; which is present in all cells including pancreatic beta cells, promotes the activity of the pro-angiogenic growth factor VEGF; so which enables the creation of new blood vessels. Therefore, it gives a higher re-vascularization of the treatment that improves islet survival and functionality.

Regulation of the re-vascularization is induce by hypoxia and the lack of nutrients; also the inhibition of phosphatase widens this response. When the stimuli disappears, the creation of new blood vessels stops, notes Rosa Gasa. This article is a proof of concept that removes one of the reasons that pancreatic islet transplant fails. There are less specific inhibitors of PTP1B and phosphatases, and therefore; so the next step will be to test these inhibitors in the islet transplant in humans; also assess its success, concludes Ramon Gomis.